Coherus Confirms Filing Plans For Ranibizumab And Bevacizumab
Both Biosimilar Filings Have Experienced Delays
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.
You may also be interested in...
US Lucentis Competition Expectations Upended By Byooviz
Samsung Bioepis’ indication that it will not launch its FDA-approved ranibizumab biosimilar, Byooviz, before June 2022 has changed what we know about the competitive landscape for Lucentis in the US.
Teva Brings In Ranibizumab Biosimilar As Bioeq Files In Europe
Biosimilar Lucentis in Europe is once again in the headlines, as Teva announced a deal to in-license Bioeq and Formycon’s FYB201 ranibizumab candidate in several key global markets.
What’s Next? Five Things To Look Out For In June
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.